How the tuberculosis jab could lead to a coronavirus vaccine
Research shows correlation between levels of TB immunisation and Covid-19 cases

A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
As the Covid-19 coronavirus spread across Europe in February and March, a surprising pattern emerged: countries with high rates of tuberculosis vaccination seemed to be succumbing more slowly.
“Eastern Europe has been less affected than the west, and even eastern Germany less than western Germany,” says The Economist.
The distribution coincides with immunisation policy, adds Euronews, which notes that “universal tuberculosis vaccination policies were widely spread in the countries of the former Soviet Union”, including the old East Germany.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Scientists have emphasised that correlation does not imply causation - with many other possible explanations for the pattern of infection - but some researchers now believe that the TB vaccination will have a role to play in fighting Covid-19.
Old vaccine, new tricks
The Bacillus Calmette–Guerin (BCG) injection, which protects against TB, is the world’s most widely used vaccine. Each year the jab is administered to around 130 million children, many of them in developing countries where TB is still endemic.
However, the vaccine has long been thought to protect children from more than just TB.
“Soon after its introduction in Europe in the 1920s, epidemiological studies reported that BCG vaccination strongly reduced infant mortality, and this could not be explained by a reduction in tuberculosis alone,” says a paper published in the journal Nature by researchers investigating whether the jab might also protect against Covid-19.
Although TB is caused by bacteria, clinical trials have shown that the BCG injection protects against viruses too, particularly those that target the throat and lungs.
According to a report published in The Lancet, the protective effect results from “changes that enhance the innate immune response to subsequent infections, a process termed trained immunity”. That means people who have had the BCG are primed to fight off a wide range of diseases.
–––––––––––––––––––––––––––––––For a round-up of the most important stories from around the world - and a concise, refreshing and balanced take on the week’s news agenda - try The Week magazine. Start your trial subscription today –––––––––––––––––––––––––––––––
Does it protect against Covid-19?
According to the World Health Organization, there is “no evidence” that the BCG works against the new coronavirus, but that may be because there hasn’t yet been time to prove the link.
In the meantime, says The Times, there is “a growing belief among some scientists [that] long-term, universal and, in some countries, mandatory vaccination” against TB offers at least some protection.
“People who have received the BCG experience a form [of Covid-19] that is easier,” Predrag Kon, Serbia’s state epidemiologist, told the newspaper.
“These are just impressions, and there is still not enough evidence to know for sure. But it does seem that the countries with universal BCG vaccinations have had an easier experience with Covid-19.”
Other potential explanations include early lockdowns, border closures and strict quarantine policies in countries with lower mortality rates.
“Political scientists in Poland and Greece say the vulnerability of health systems in Eastern Europe spurred leaders into decisive action, while governments in the west felt a ‘greater sense of complacency’,” reports the Daily Mail.
Clinical trials now under way in the Netherlands and Australia are expected to provide more insight into the possible role of the BCG vaccine.
Professor Mihai Netea, who is leading the Dutch research, said that even if the TB jab doesn’t offer comprehensive protection against the coronavirus, it “may well be a bridge to a specific Covid-19 vaccine” - which is likely to take a year or more to develop.
Why not vaccinate anyway?
Since the BCG is so widely and safely used, it may seem sensible to vaccinate first and gather the evidence afterwards. But public health officials put forward two reasons for a more cautious approach.
One is that if the vaccine turns out to be ineffective, receiving it could lead to a false sense of security. And that could encourage riskier behaviour that leads to the virus spreading more quickly.
The other issue is that lives are at risk elsewhere. “The BCG vaccine is already in short supply, and indiscriminate use could jeopardise the supply needed to protect children against tuberculosis in high-risk areas,” says The Lancet report.
–––––––––––––––––––––––––––––––For a round-up of the most important stories from around the world - and a concise, refreshing and balanced take on the week’s news agenda - try The Week magazine. Start your trial subscription today –––––––––––––––––––––––––––––––
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
-
Is Donald Trump finished in New York?
Today's Big Question How the former president's fraud ruling could ruin him in the city that made him famous
By Rafi Schwartz Published
-
Windmill whales
Cartoons
By The Week Staff Published
-
Why the FTC antitrust lawsuit against Amazon is so consequential
Talking Point While it's not the first case the federal agency brought against the company, it might be the biggest challenge yet
By Theara Coleman Published
-
You can now get a new Covid booster shot. Should you?
Unless you are old or otherwise at high risk, it isn't a 'slam dunk'
By Peter Weber Published
-
New Covid variant BA.2.86: does the UK booster programme go far enough?
Talking Point Some MPs and experts say criteria for jabs is ‘too narrow’ ahead of ‘rocky ride’ this winter
By Chas Newkey-Burden Published
-
Covid testing to be ramped up for winter
Speed Read Scientists fear UK could be ‘flying blind’ on infection rates due to lack of monitoring programmes
By Harriet Marsden Published
-
Is it time to mask up again?
Today's Big Question A rise in Covid-19 cases brings back the possibility of mask mandates
By Joel Mathis Published
-
The NHS plan for virtual wards to beat winter crisis
feature Patients with respiratory infections to be given wearable devices that allow doctors to monitor them at home
By The Week Staff Published
-
Understanding the new Covid-19 variant, Eris
Speed Read The formally named EG.5 is making the rounds, but we don't have to worry just yet
By Devika Rao Published
-
The new Covid variant Eris behind a rise in cases this summer
feature Concerns over ’flying blind’ as routine testing is no longer freely available and less data is being collected
By Felicity Capon Published
-
The new push to solve long Covid
Speed Read Patients say researchers have been too slow to address the condition
By Joel Mathis Published